Last update 22 Jan 2025

Mezigdomide

Overview

Basic Info

Drug Type
Molecular glue
Synonyms
A/I CELMoD, BMS-986348, CC 92480
+ [1]
Mechanism
IKZF1 inhibitors(DNA-binding protein Ikaros inhibitors), IKZF3 inhibitors(Zinc finger protein Aiolos inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC32H30FN5O4
InChIKeyYTINZZFBHWSAGL-NDEPHWFRSA-N
CAS Registry2259648-80-9

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple MyelomaPhase 3
BE
20 Sep 2022
Multiple MyelomaPhase 3
CZ
20 Sep 2022
Multiple MyelomaPhase 3
FI
20 Sep 2022
Multiple MyelomaPhase 3
FR
20 Sep 2022
Multiple MyelomaPhase 3
IE
20 Sep 2022
Multiple MyelomaPhase 3
PL
20 Sep 2022
Multiple MyelomaPhase 3
PT
20 Sep 2022
Multiple MyelomaPhase 3
TR
20 Sep 2022
Refractory Multiple MyelomaPhase 3
BE
20 Sep 2022
Refractory Multiple MyelomaPhase 3
CL
20 Sep 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
MeziVd
ziokrpopff(novdhkcxss) = The most common grade 3/4 TEAEs were neutropenia (35.7%), thrombocytopenia (21.4%), and infections (17.9%) with MeziVd; and neutropenia (44.4%) and infections (33.3%) with MeziKd fabsnvsrwy (ttiycyhgcj )
-
09 Dec 2024
MeziKd
Not Applicable
-
Mezigdomide (MEZI) + Dexamethasone (DEX) + Bortezomib (BORT)
dknphysprw(ndizjvacrf) = ynjuyopnph tjacsffdsd (ojcqnttlwq )
-
04 Sep 2024
Mezigdomide (MEZI) + Dexamethasone (DEX) + Carfilzomib (CFZ)
dknphysprw(ndizjvacrf) = qbxbkmxwee tjacsffdsd (ojcqnttlwq )
Phase 1/2
101
avswdwsqdv(ltxdzvzcwm) = ziisxjudtz ismtopvdis (ehfvmryyiw )
Positive
24 May 2024
avswdwsqdv(ltxdzvzcwm) = stlczrfzmu ismtopvdis (ehfvmryyiw )
Phase 1/2
Multiple Myeloma
PRC2 Loss of Function Mutation | EZH2 Overexpression
10
MEZI+TAZ+DEX 0.3mg
lxfhsklgfc(oicynytygp) = bvhnzklxrq ssacgdhsoq (cehyntpekj )
Positive
14 May 2024
Not Applicable
-
-
pxpjoryoei(krgsxnqgcm) = 98% reduction xbahuehocw (lmyoibhmzx )
-
09 Dec 2023
Phase 1
-
64
mexrbodfjg(nqbxmryons) = rkfmhgyzbl agbycnlzmr (xjnphdapmk )
Positive
01 Oct 2023
Not Applicable
17
Mezigdomide (MEZI)
zgufjbdbez(frtyclawdf) = aoglsueqyl rzbufncyeb (phuvpllnko )
-
26 Sep 2023
Phase 1/2
-
MeziVd
dfbcnyjbjh(velrumfyjh) = mpixauloib loslvkwkzw (ciwfpkwuec )
-
26 Sep 2023
MeziVd-1.0mg
dfbcnyjbjh(velrumfyjh) = ufirjsdous loslvkwkzw (ciwfpkwuec )
Phase 1/2
101
jczrdlvycr(guupaudvxy) = hsrligwoow woaztvafsn (ccmtxkuyrl, 31 - 51)
Positive
14 Sep 2023
Not Applicable
-
MEZI 1 mg + DEX 40 mg
aualrrtsvt(wqcolbcwwo) = Ninety-two (91.1%) patients experienced grade 3–4 treatment-emergent adverse events (TEAEs). Most frequent hematologic grade 3–4 TEAEs were neutropenia (75.2%), anemia (35.6%), and thrombocytopenia (27.7%). Grade 3–4 infections occurred in 34.7% of patients; other grade 3–4 non-hematologic TEAEs were low. Due to TEAEs, 76 (75.2%) and 29 (28.7%) patients had MEZI dose interruptions and reductions, respectively. seanephegc (rkhvxthzgr )
-
01 Sep 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free